CLAL BIOTECHNOLOGY (Israel) Management Performance Evaluation

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 35px;;'>CLA</div>
Analysis of CLAL BIOTECHNOLOGY manpower and management performance that can provide insight into the company performance. Note, an employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with CLAL BIOTECHNOLOGY future performance. CLAL BIOTECHNOLOGY employes about 14 people. The company is managed by 15 executives with total tenure of roughly 124 years, averanging almost 8.0 years of service per executive having 1.0 employee per reported executive. Continue to Trending Equities.
  Avraham Fischer  Chairman
Chairman of the Board
  Ofer Gonen  President
Vice President
  Julian Adams  President
President Chief Scientific Officer

CLAL BIOTECHNOLOGY Management Effectiveness

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.

CLAL BIOTECHNOLOGY Workforce Comparison

CLAL BIOTECHNOLOGY is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 28.0. CLAL BIOTECHNOLOGY totals roughly 14.0 in number of employees claiming about 50% of stocks in Biotechnology industry.


The company has Profit Margin (PM) of (256.81) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (667.44) % which suggests for every $100 dollars of sales it generated a net operating loss of -6.67.


Avraham Fischer Chairman of the Board
Ofer Gonen Vice President
Julian Adams President Chief Scientific Officer
Assaf Segal CFO
Sigalia Heifetz Director
Shmuel Rubinstein External Director
Tomer Babai Director
Dafna Gruber Director
Aharon Schwartz Director
Gavriel Barabash Director
Isaac Kohlberg Director
Nofar Malovani Director
Yuval Yanai External Director
Ofer Goldberg VP
Orit Lidor VP and General Counsel

CLAL BIOTECHNOLOGY Manpower Efficiency


Revenue Per Employee877.9 K
Revenue Per Executive819.3 K
Net Loss Per Employee2.3 M
Net Loss Per Executive2.1 M
Working Capital Per Employee13.8 M
Working Capital Per Executive12.9 M
Continue to Trending Equities. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Company logos by clearbit